Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I/ Phase II
Sponsor : Syncona
Deal Size : $83.0 million
Deal Type : Series B Financing
Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Details : The proceeds will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy for the treatment of end-stage liver disease.
Brand Name : RTX001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 02, 2024
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Sponsor : Syncona
Deal Size : $83.0 million
Deal Type : Series B Financing
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Resolution Therapeutics Gets MHRA Approval for Phase I/II EMERALD Study RTX001
Details : RTX001 is an engineered autologous macrophage cell therapy designed to deliver anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease like decompensated liver cirrhosis.
Brand Name : RTX001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 27, 2024
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
